Abiraterone, Enzalutamide, Darolutamide, and Apalutamide: How Oncologists Decide

A regional roundtable discussion, moderated by Gregg Franklin, MD, PhD, New Mexico Cancer Center, explored current and emerging strategies in the management of metastatic castration-sensitive and castration-resistant prostate cancer, including clinical trial data, treatment sequencing, toxicity management, and the future role of targeted therapies and radiopharmaceuticals in patient care. Dr. Franklin was joined by other practitioners in the greater Albuquerque area, including Kathryn Chan, MD, Nexus Health; Laura Onorato, PA, New Mexico Cancer Center; Jose Avitia, MD, New Mexico Cancer Center; and Scott Herbert, MD, Nexus Health. In the fourth segment, the panel highlights second-generation anti-androgens and their selection for patients with metastatic castrate-sensitive prostate cancer. They also explore radiographic versus PSA progression, triplet therapy in high-risk patients, and strategies for sequencing treatment and incorporating radium in metastatic castrate-resistant disease to maximize patient outcomes.